[Survival in cancers of the piriform sinus after induction chemotherapy].
285 cases of primary squamous cell carcinoma of pyriform sinus were treated by initial surgery completed by radiation. 242 patients received neo-adjuvant chemotherapy: Bleomycin as single agent (n = 95), Vincristine-Methotrexate-Bleomycin or Endoxan: 3 courses (n = 98), CDDP-Bleomycin, 5 FU or Methotrexate: 3 courses (n = 40). Chemotherapy was not administrated to 43 patients. Actuarial survival at 3 years without chemotherapy was 30%, after Bleomycin: 31%, VMB-VME: 47%, CMB-CFB: 61%. The 5-year survival without chemotherapy was 17%, with Bleomycin: 28%, with VMB-VME: 32%. Actuarial survival at 5-year including only deaths due to cancer was 13% without chemotherapy, 29% with Bleomycin and 39% with VMB-VME. This increasing of survival was directly related to improvement of locoregional prognosis.
Brasnu
D
D
Lacau-St-Guily
J
J
Fabre
A
A
Menard
M
M
Bassot
V
V
Laccourreye
H
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010610:Pharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies
D001761:Bleomycin
La survie dans les cancers du sinus piriforme après chimiothérapie d'induction.